Shanghai Junjie Biotechnology

Shanghai Junjie Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to developing innovative therapies for metabolic and chronic liver diseases. The company focuses on high-prevalence conditions with significant unmet needs, such as non-alcoholic steatohepatitis (NASH), obesity, and type 2 diabetes. Its lead candidate, JJZ202, is a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, currently undergoing clinical evaluation for weight management and glycemic control. Additionally, the company is advancing JJZ101, a small molecule farnesoid X receptor (FXR) agonist for the treatment of NASH. Backed by leading venture capital firms like Qiming Venture Partners and Lilly Asia Ventures, Junjie Biotechnology aims to leverage its R&D expertise to deliver next-generation metabolic treatments to the global market.